BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 9726451)

  • 1. Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck.
    Fischbein NJ; AAssar OS; Caputo GR; Kaplan MJ; Singer MI; Price DC; Dillon WP; Hawkins RA
    AJNR Am J Neuroradiol; 1998 Aug; 19(7):1189-96. PubMed ID: 9726451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer.
    Hanasono MM; Kunda LD; Segall GM; Ku GH; Terris DJ
    Laryngoscope; 1999 Jun; 109(6):880-5. PubMed ID: 10369275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Results of pretherapeutic lymph node diagnosis in head and neck tumors. Clinical value of 18-FDG positron emission tomography (PET)].
    Di Martino E; Nowak B; Krombach GA; Sellhaus B; Hausmann R; Cremerius U; Büll U; Westhofen M
    Laryngorhinootologie; 2000 Apr; 79(4):201-6. PubMed ID: 10838683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma.
    Wong WL; Chevretton EB; McGurk M; Hussain K; Davis J; Beaney R; Baddeley H; Tierney P; Maisey M
    Clin Otolaryngol Allied Sci; 1997 Jun; 22(3):209-14. PubMed ID: 9222623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment.
    Yao M; Smith RB; Graham MM; Hoffman HT; Tan H; Funk GF; Graham SM; Chang K; Dornfeld KJ; Menda Y; Buatti JM
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):991-9. PubMed ID: 16099601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Staging of head and neck tumors: [18F]fluorodeoxyglucose positron emission tomography compared with physical examination and conventional imaging modalities.
    Sigg MB; Steinert H; Grätz K; Hugenin P; Stoeckli S; Eyrich GK
    J Oral Maxillofac Surg; 2003 Sep; 61(9):1022-9. PubMed ID: 12966477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorine-18 fluorodeoxyglucose imaging using dual-head coincidence positron emission tomography without attenuation correction in patients with head and neck cancer.
    Pai M; Park CH; Suh JH; Koh JH
    Clin Nucl Med; 1999 Jul; 24(7):495-500. PubMed ID: 10402001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography.
    Farber LA; Benard F; Machtay M; Smith RJ; Weber RS; Weinstein GS; Chalian AA; Alavi A; Rosenthal DI
    Laryngoscope; 1999 Jun; 109(6):970-5. PubMed ID: 10369292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of (18) FDG PET-CT for treatment evaluation 3 months after completion of chemoradiotherapy for head and neck squamous cell carcinoma: 2-year minimum follow-up.
    Sagardoy T; Fernandez P; Ghafouri A; Digue L; Haaser T; de Clermont-Galleran H; Castetbon V; de Monès E
    Head Neck; 2016 Apr; 38 Suppl 1():E1271-6. PubMed ID: 26315809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of 18F-FDG PET in detecting primary site in the patient with primary unknown carcinoma.
    Yabuki K; Tsukuda M; Horiuchi C; Taguchi T; Nishimura G
    Eur Arch Otorhinolaryngol; 2010 Nov; 267(11):1785-92. PubMed ID: 20814690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymph node metastasis of squamous cell carcinoma from an unknown primary: impact of positron emission tomography.
    Stoeckli SJ; Mosna-Firlejczyk K; Goerres GW
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):411-6. PubMed ID: 12634970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of PET FDG in the management of head and neck squamous cell cancer.
    Wong WL; Saunders M
    Clin Oncol (R Coll Radiol); 1998; 10(6):361-6. PubMed ID: 9890536
    [No Abstract]   [Full Text] [Related]  

  • 14. Positron emission tomography in the evaluation of the negative neck in patients with oral cavity cancer.
    Myers LL; Wax MK
    J Otolaryngol; 1998 Dec; 27(6):342-7. PubMed ID: 9857320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma.
    Cetina L; Serrano A; Cantú-de-León D; Pérez-Montiel D; Estrada E; Coronel J; Hernández-Lucio M; Dueñas-González A
    Rev Invest Clin; 2011; 63(3):227-35. PubMed ID: 21888286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study.
    Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S
    Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography/computerized tomography (PET/CT) scanning for preoperative staging of patients with oral/head and neck cancer.
    Nahmias C; Carlson ER; Duncan LD; Blodgett TM; Kennedy J; Long MJ; Carr C; Hubner KF; Townsend DW
    J Oral Maxillofac Surg; 2007 Dec; 65(12):2524-35. PubMed ID: 18022480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck.
    Ng SH; Yen TC; Chang JT; Chan SC; Ko SF; Wang HM; Lee LY; Kang CJ; Wong AM; Liao CT
    J Clin Oncol; 2006 Sep; 24(27):4371-6. PubMed ID: 16983105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic performance of
    Chaput A; Robin P; Podeur F; Ollivier M; Keromnes N; Tissot V; Nonent M; Salaün PY; Rousset J; Abgral R
    Laryngoscope; 2018 Feb; 128(2):378-385. PubMed ID: 28600822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.